Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04817072 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease

Study acronym: EMOTION
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 9, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: May 2024 to Nov 2025
    • Study completion date: Sep 2024 to May 2026
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: May 2022 to May 2024
    • Study completion date: Sep 2022 to Sep 2024
    • Start date changed from estimate of Apr 2021 to May 19, 2021
    • Secondary endpoints: details revised at 5 of 6 entries
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.
Trial Details
NCT Number NCT04817072
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Conditions
(from sponsor)		 Rheumatic Diseases, Mood Disorders
Related terms Mood Disorders, Rheumatic Diseases
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov